Pricing Log in Create free account
Friday 6 November 2026 Export COR’s income statement to Excel — free account

Cencora, Inc.

COR Healthcare Medical Distribution

Cencora, Inc.’s revenue for fiscal 2026 (year ended September 2026) was $337.4 billion, up 5.00% from fiscal 2025.

Revenue
+5.52%
EPS
+258.4%
Free cash flow
−7.81%
Total debt
+47.1%

Quarter to September 2026, against a year earlier

334.21 5.47 −1.61%
Market cap
$64.8B
P/E
18.8×
Fwd P/E
17.5×
Dividend yield
0.71%
F-score
7/9
Altman Z
n/a
Beneish M
−2.59
Dividend safety
70/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Cencora, Inc. 10-Q filed Aug 5, 2026

Fiscal Q3 2026 · Period ended Jun 30, 2026 · Filed · accepted 3:23 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 6, 2026: 6 added · 5 removed · 47 modified; 26 with only figures updated; 1 moved without change

  1. Removed · Recent Development

    On February 2, 2026, we acquired the majority of the outstanding equity interests that we did not previously own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, for total fair value consideration of $7,387.1 million, which included cash consideration of $4,648.7 million, $1,934.2 million of fair value of our previously held equity method investment, $752.1 million of estimated contingent consideration for certain OneOncology physicians and members of management that retained an 8% interest in OneOncology, and $52.0 million for the settlement of a receivable resulting from a pre-existing commercial arrangement between us and OneOncology. We funded the transaction through a combination of new debt financing (see Note 7 of the Notes to Consolidated Financial Statements) and cash on-hand. We believe the acquisition of OneOncology allows us to broaden our relationships with community oncology providers and to build on our leadership in specialty pharmaceuticals within our U.S. Healthcare Solutions reportable segment.